Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis

Phase 2 Unknown 200 enrolled Green Cross Corporation C&R Research, Inc. · collab CRScube · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of the investigational products in the patients with gastritis during their participation in the study.

Timeline

Start: 2014-09
Primary completion: 2015-07
Completion: 2015-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GC6101A	Unknown	12.5 mg	—
Subject	GC6101A	Unknown	25 mg	—
Subject	GC6101A	Unknown	50 mg	—

Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis

Summary

Timeline

Drugs

Indications